2011

• Cuzick J, Decensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011 May;12(5):496-503.
• DeCensi A, Gennari A. Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol. 2011 Jan 1;29(1):7-10.
• DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G, Bonanni B. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol. 2011 Mar;22(3):582-7.
• Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D,  Macis D, Johansson H, Pala O, Luini A, Veronesi P, Galimberti V, Dotti MC, Viale G, Bonanni B. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila). 2011 Aug;4(8):1181-9.
• Gennari A, D'amico M, Corradengo D. Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review. Ther Adv Med Oncol. 2011 Sep;3(5):229-32.
• Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D'Amico M, Decensi A, Bruzzi P. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011 Jun 1;29(16):2144-9.
• Ghiorzo P, Pensotti V, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bonelli L, Borgonovo G, Bruno W, Gozza A, Gargiulo S, Mastracci L, Nasti S, Palmieri G, Papadia F, Pastorino L, Russo A, Savarino V, Varesco L, Bernard L, Bianchi Scarrà G; for the Genoa Pancreatic Cancer Study Group. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.  Fam Cancer. 2011 Oct 12.
• Giorgio E, Caroti C, Mattioli F, Uliana V, Parodi MI, D'Amico M, Fucile C, Marini V, Forzano F, Cassola G, Martelli A, Faravelli F, Di Maria E. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemother Pharmacol. 2011 Aug 11.
• Greco MT, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone G; Writing Protocol Committee; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Epidemiology and pattern of care of breakthrough cancer pain in a  longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain. 2011 Jan;27(1):9-18. (Caroti C.)
• Lazzeroni M, Gandini S, Puntoni M, Bonanni B, Gennari A, Decensi A. The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it. Breast. 2011 Oct;20 Suppl 3:S36-41.
• Maisonneuve P, Bagnardi V, Bellomi M, Spaggiari L, Pelosi G, Rampinelli C,Bertolotti R, Rotmensz N, Field JK, Decensi A, Veronesi G. Lung Cancer Risk Prediction to Select Smokers for Screening CT--a Model Based on the Italian COSMOS Trial. Cancer Prev Res (Phila). 2011 Oct 18.
• Montironi R, Bartels PH, Decensi A, Puntoni M, Hurle R, Decobelli O, Carmignani G, Mazzucchelli R, Bartels HG, Alberts DS, Maffezzini M. A randomized  phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in  men with prostate cancer. Efficacy monitored by karyometry☆. Urol Oncol. 2011 Jul 21.
• Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, Sonzogni A, Veronesi G, Spaggiari L, Papotti M, Barbareschi M, Graziano P, Decensi A, Cavazza A, Viale G. Immunhistochemistry by Means of Widely Agreed-Upon Markers (Cytokeratins 5/6 and 7, p63, Thyroid Transcription Factor-1, and Vimentin) on Small Biopsies of Non-small Cell Lung Cancer Effectively Parallels the Corresponding Profiling and Eventual Diagnoses on Surgical Specimens. J Thorac Oncol. 2011 Jun;6(6):1039-1049.
• Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One. 2011 Apr 29;6(4):e19234.
• Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H, Guerrieri-Gonzaga A, Plebani M, Basso D, Gjerde J, Mellgren G, Rotmensz N, Decensi A, Bonanni B. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics  J. 2011 Apr;11(2):100-7.
• Veronesi G, Szabo E, Decensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Ferretti S, Pelosi G, Lazzeroni M, Serrano D, Lippman SM, Spaggiari L, Nardi-Pantoli A, Harari S, Varricchio C, Bonanni B.
  Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila). 2011 Jan;4(1):34-42.

2010

• DeCensi A, Gennari A. Insulin Breast Cancer Connection: Confirmatory Data Set the Stage for Better Care. J Clin Oncol. 2010 Nov 29.
• DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G, Bonanni B. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol. 2010 Aug 17.
• Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis. Cancer Prev Res (Phila). 2010 Oct 12.
• Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, Rotmensz N, Goldhirsch A, Varricchio C, Serrano D, Cazzaniga M, Bassi F, Luini A, Bagnardi V, Viale G, Mora S, Bollani G, Albertazzi E, Bonanni B, Decensi A. Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. Ann Oncol. 2010 May;21(5):949-54.
• Haugan Moi LL, Hauglid Flågeng M, Gandini S, Guerrieri-Gonzaga A, Bonanni B, Lazzeroni M, Gjerde J, Lien EA, DeCensi A, Mellgren G. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clin Cancer Res. 2010 Apr 1;16(7):2176-86.
• Maffezzini M, Campodonico F, Capponi G, Canepa G, Casazza S, Bandelloni R, Tamagno S, Puntoni M. Prognostic Significance of Fluorescent In Situ Hybridisation in the Follow-up of Non-muscle-invasive Bladder Cancer. Anticancer Res. 2010 Nov;30(11):4761-5.
• Morasso G, Di Leo S, Caruso A, DeCensi A, Beccaro M, Berretta L, Bongiorno L, Cosimelli M, Finelli S, Rondanina G, Santoni W, Stigliano V, Costantini M. Evaluation of a screening programme for psychological distress in cancer survivors. Support Care Cancer. 2010 Dec;18(12):1545-52.

• Puzone R, Paleari L, Montefiore F, Ruggiero L, Puntoni M, Maffezzini M, Bobbio B, Marroni P, Libener R, Betta PG. Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy. Int J Biol Markers. 2010 Oct-Dec;25(4):200-6

• Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H, Guerrieri-Gonzaga A, Plebani M, Basso D, Gjerde J, Mellgren G, Rotmensz N, Decensi A, Bonanni B. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics J. 2010 Mar 23.
• Sogno I, Venè R, Ferrari N, DeCensi A, Imperatori A, Noonan DM, Tosetti F, Albini A. Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies. Crit Rev Oncol Hematol. 2010 Jul;75(1):2-14.
• Tagliafico AS, Ameri P, Bovio M, Puntoni M, Capaccio E, Murialdo G, Martinoli C. Relationship between fatty degeneration of thigh muscles and vitamin D status  in the elderly: a preliminary MRI study. AJR Am J Roentgenol. 2010 Mar;194(3):728-34.

2009

• Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators.
  Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer. 2009 May 19;100(10):1566-74.
• Aschele C, Bergamo F, Lonardi S.
  Chemotherapy for operable and advanced colorectal cancer. Cancer Treat Rev. 2009 Oct;35(6):509-16
• Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D, Cazzaniga M, Luini A, Cassano E, Oldani S, Lien EA, Pelosi G, Decensi A.
  Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia. Clin Cancer Res. 2009 Nov 15;15(22):7053-60.
• Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A.
  Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):701-5.
• Cazzaniga M, Decensi A, Bonanni B, Luini A, Gentilini O.
  Biomarkers for risk assessment and prevention of breast cancer. Curr Cancer Drug Targets. 2009 Jun;9(4):482-99.
• Cazzaniga M, Gheit T, Casadio C, Khan N, Macis D, Valenti F, Miller MJ, Sylla BS, Akiba S, Bonanni B, Decensi A, Veronesi U, Tommasino M.
  Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis. Breast Cancer Res Treat. 2009 Apr;114(3):599-605
• Colombo BM, Cacciapaglia F, Puntoni M, Murdaca G, Rossi E, Rodriguez G, Nobili F, Pisciotta L, Bertolini S, Moccetti T, Dentali F, Steidl L, Ciprandi G, Afeltra A, Indiveri F, Puppo F.
  Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev. 2009 Feb;8(4):309-15.
• Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E, Moroni SM, Formelli F, Lien EA, Pelosi G, Johnson KA, Bonanni B.
  Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol. 2009 Aug 10;27(23):3749-56.
• Forni GL, Puntoni M, Boeri E, Terenzani L, Balocco M.
  The influence of treatment in specialized centers on survival of patients with thalassemia major. Am J Hematol. 2009 May;84(5):317-8.
• Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, Rotmensz N, Goldhirsch A, Varricchio C, Serrano D, Cazzaniga M, Bassi F, Luini A, Bagnardi V, Viale G, Mora S, Bollani G, Albertazzi E, Bonanni B, Decensi A.
  Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. Ann Oncol. 2009 Oct 25.
• Guerrieri-Gonzaga A, Botteri E, Rotmensz N, Bassi F, Intra M, Serrano D, Renne G, Luini A, Cazzaniga M, Goldhirsch A, Colleoni M, Viale G, Ivaldi G, Bagnardi V, Lazzeroni M, Decensi A, Veronesi U, Bonanni B.
  Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years. Oncologist. 2009 Mar;14(3):201-12.
• Maffezzini M, Campodonico F, Puntoni M, Martelli A, Mattioli F.
  Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer. Urology. 2009 Nov;74(5):1078-83.
• Morasso G, Di Leo S, Caruso A, Decensi A, Beccaro M, Berretta L, Bongiorno L, Cosimelli M, Finelli S, Rondanina G, Santoni W, Stigliano V, Costantini M.
  Evaluation of a screening programme for psychological distress in cancer survivors. Support Care Cancer. 2009 Nov 18.
• Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L.
  Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009 Jun 1;69(11):4598-604.
• Puntoni M, Bonanni B, Decensi A.
  Dietary changes after breast cancer in women without hot flashes: a simple and inexpensive way to target tumor and host? J Clin Oncol. 2009 Jan 20;27(3):323-5.
• Puntoni M, Decensi A.
  The rationale and potential of cancer chemoprevention with special emphasis on breast cancer. Eur J Cancer. 2009 Sep;45 Suppl 1:346-54.
• Zanardi S, Puntoni M, Maffezzini M, Bandelloni R, Mori M, Argusti A, Campodonico F, Turbino L, Branchi D, Montironi R, Decensi A.
  Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies. Cancer Prev Res (Phila Pa). 2009 Apr;2(4):377-84.

2008

• Puntoni M, Marra D, Zanardi S, Decensi A. Inflammation and cancer prevention. Ann Oncol. 2008 Sep;19 Suppl 7:vii225-9. Review
• Johansson H, Gandini S, Guerrieri-Gonzaga A, Iodice S, Ruscica M, Bonanni B, Gulisano M, Magni P, Formelli F, Decensi A. Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res. 2008 Nov 15;68(22):9512-8
• Cazzaniga M, Gheit T, Casadio C, Khan N, Macis D, Valenti F, Miller MJ, Sylla BS, Akiba S, Bonanni B, Decensi A, Veronesi U, Tommasino M. Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis. Breast Cancer Res Treat. 2008 May 9
• Rondanina G, Puntoni M, Severi G, Varricchio C, Zunino A, Feroce I, Bonanni B, Decensi A. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol. 2008 Mar 20;26(9):1537-43
• Colombo BM, Cacciapaglia F, Puntoni M, Murdaca et all. Traditional and nontraditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: Role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev. 2008 Oct 28
• Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, et all. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.J Natl Cancer Inst. 2008 Jan 2;100(1):14-20.
• Puntoni M, Bonanni B, Decensi A. Dietary Changes After Breast Cancer in Women Without Hot Flashes: A Simple and Inexpensive Way to Target Tumor and Host? J Clin Oncol. 2008 Dec 15
• Serrano D, Gandini S, Mariani L, Bonanni B, Santinelli A, Guerrieri-Gonzaga A, Pelosi G, Cassano E, Montironi R, Decensi A. Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users. Breast. 2008 Feb;17(1):91-7
• Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, Cassano E, Ramazzotto F, Baglietto L, Sandri MT, Decensi A. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat. 2008 Mar;108(1):57-67
• Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, Marroni P, Grossi F, Paganuzzi M. Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. Anticancer Res. 2008 Jan-Feb;28(1B):507-13
• Maffezzini M, Capponi G, Casazza S, Campodonico F, Bandelloni R, Puntoni M. The UroVysion F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer. Arch Ital Urol Androl. 2008 Dec;80(4):127-31

2007

• Serrano D, Gandini S, Mariani L, Bonanni B, Santinelli A, Guerrieri-Gonzaga A, Pelosi G, Cassano E, Montironi R, Decensi A. Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users. Breast. 2007 Sep 1
• Decensi A, Gandini S, Serrano D, Cazzaniga M, Pizzamiglio M, et all. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol. 2007 Sep 20;25(27):4201-9
• Puntoni M, Zanardi S, Branchi D, Bruno S, Curotto A, Varaldo M, Bruzzi P, Decensi A. Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder  cancer. Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):979-83
• Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A; Italian Tamoxifen Study Group.  Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007 May 2;99(9):727-37
• Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, Cassano E, Ramazzotto F, Baglietto L, Sandri MT, Decensi A.  Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat. 2007 Apr 28
• Veronesi U, Maisonneuve P, Decensi A. Tamoxifen: an enduring star. J Natl Cancer Inst. 2007 Feb 21;99(4):258-60
• Macis D, Maisonneuve P, Johansson H, Bonanni B, Botteri E, Iodice S, Santillo  B, Penco S, Gucciardo G, D'Aiuto G, Rosselli Del Turco M, Amadori M, Costa A, Decensi A.  Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat. 2007 Dec;106(2):263-71
• Decensi A, Zanardi S, Argusti A, Bonanni B, Costa A, Veronesi U. Fenretinide and risk reduction of second breast cancer. Nat Clin Pract Oncol. 2007 Feb;4(2):64-5
• Aschele C, Lonardi S. Multidisciplinary treatment of rectal cancer: medical oncology. Ann Oncol. 2007 Jul;18 Suppl 9:ix114-21. Review. Ann Oncol. 2007 Nov;18(11):1908-15
• Aschele C, Lonardi S.  Addition of weekly oxaliplatin to standard preoperative chemoradiation for locally advanced rectal cancer. J Clin Oncol. 2007 Feb 10;25(5):602-3; author reply 603
• Mustacchi G, et all; NORA Study Group (includes D'Amico M e A. Gozza) Breast cancer in elderly women: a different reality? Results from the NORA study Ann Oncol18 (6) 11991-996
• Cazzaniga ME, Mustacchi G, et all; NORA Study Group (includes D'Amico M e A. Gozza) Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study Ann Oncol18 (12) 121976-80

2006

• Colombo N, Formelli F, Cantu MG, Parma G, Gasco M, Argusti A, Santinelli A, Montironi R, Cavadini E, Baglietto L, Guerrieri-Gonzaga A, Viale G, Decensi A. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1914-9
• Serrano D, Mariani L, Mora S, Guerrieri-Gonzaga A, Cazzaniga M, Daldoss C, Ramazzotto F, Feroce I, Decensi A, Bonanni B. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT. Maturitas. 2006 Aug 20;55(1):69-75
• Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU.  Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol. 2006 Aug 1;24(22):3708-9; author reply 3709
• Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB, De Palo G. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol. 2006 Jul;17(7):1065-71
• Johansson H, Bonanni B, Mariette F, Cazzaniga M, Baglietto L, Guerrieri-Gonzaga A, Sandri MT, Luini A, Pelosi G, Decensi A. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer. Breast Cancer Res Treat. 2006 Jul;98(2):167-72
• Cazzaniga M, Severi G, Casadio C, Chiapparini L, Veronesi U, Decensi A.
  Atypia and Ki-67 expression from ductal lavage in women at different risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1311-5
• Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer. 2006 Mar;13(1):51-68. Review
• Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Formelli F, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, Decensi A. Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol. 2006 Jan 1;24(1):129-35
• Pucciarelli S, Urso E, DeSalvo GL, Aschele C, Friso ML, Rugge M, Toppan P, Bruttocao A, Fabris G, Ferraro B, Lonardi S, Frego M, Finco C, Lise M, Nitti D. 5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results.
  Arch Med Res. 2006 Oct;37(7):860-5
• Urso E, Serpentini S, Pucciarelli S, De Salvo GL, Friso ML, Fabris G, Lonardi S, Ferraro B, Bruttocao A, Aschele C, Nitti D. Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer. Eur J Surg Oncol. 2006 Dec;32(10):1201-8

2005

• Boccardo F, Puntoni M, Guglielmini P, Rubagotti A. Enterolactone as a risk factor for breast cancer: a review of the published evidence. Clin Chim Acta. 2006 Mar;365(1-2):58-67. Epub 2005 Sep 15. Review
• Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U; Italian Tamoxifen Study Group. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005 Feb 8;111(5):650-6
• Serrano D, Baglietto L, Johansson H, Mariette F, Torrisi R, Onetto M, Paganuzzi M, Decensi A. Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer. Clin Cancer Res. 2005 Mar 1;11(5):2083-8
• Marenghi C, Guglielmini P, Verri E, Parodi M, Puntoni M, Usset A, Massoni C, Vormola R, Boccardo F. Impact of concurrent radiotherapy on chemotherapy total dose and dose intensity in patients with early breast cancer. Tumori. 2005 Mar-Apr;91(2):126-30
• Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Sacchini V, Decensi A, Veronesi U. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005 Apr 23;330(7497):932
• Puntoni R, Ceppi M, Casella C, Ugolini D, Gennaro V, Puntoni M, Vercelli M, Merlo DF. Increased incidence of cutaneous malignant melanoma among longshoremen in Genoa, Italy: the role of sunlight and occupational exposure. Occup Environ Med. 2005 Apr;62(4):270
• Bernardi M, Catania G, Marceca F. [The world of nursing burnout. A literature review] Prof Inferm. 2005 Apr-Jun;58(2):75-9
• Gasco M, Argusti A, Bonanni B, Decensi A. SERMs in chemoprevention of breast cancer. Eur J Cancer. 2005 Jun 15
• Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED, Del Bianco P, Sotti G, Lise M, Monfardini S. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol. 2005 Jul;16(7):1140-6
• Del Mastro L, Bruzzi P, Nicolo G, Cavazzini G, Contu A, D'Amico M, Lavarello A, Testore F, Castagneto B, Aitini E, Perdelli L, Bighin C, Rosso R, Venturini M. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer. 2005 Jul 11;93(1):7-14
• Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, Rubagotti A, Ragni N, Boccardo F. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology. 2005;68(2-3):154-6
• Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005 Aug 1;23(22):5138-47
• Boccardo F, Puntoni M, Guglielmini P, Rubagotti A. Enterolactone as a risk factor for breast cancer: A review of the published evidence. Clin Chim Acta. 2005 Sep 13
• Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, and Decensi A. Preliminary results on safety and activity of a randomized double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 2005 Dec 24:129-135
• Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention Endocrine-Related Cancer (2005) 13 1-18
• Johansson H, Bonanni B, Mariette F, Cazzaniga M, Baglietto L, Guerrieri-Gonzaga A, Sandri MT, Luini A, Pelosi G, Decensi A. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal 5 women with primary breast cancer Breast Cancer Res Treat (in press)
• F.Boccardo, A.Rubagotti, B.Agostana, D.Aldrighetti, F.Buzzi, C.Caroti, G.Cruciali, A.Farris, P.Gugliemini, M.Mesiti, G.Mustacchi, M.Porpiglia, M.Rinaldini and others GROCTA 4Bis and The Italian Tamoxifen Anastrozole ITA Trials : "Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma. Pooled analysis of two consecutive trials" Journal of Clincal Oncology 23 (22) : 5138- 5147, 2005
• M.Venturini, L.Del Mastro, E.Aitini, E.Baldini, C.Caroti, A.Contu, F.Testore, F.Brema, P.Pronzato, G.Cavazzini, M.R.Sertoli, G.Canavese, R.Rosso and P.Bruzzi "Dose dense adjuvant chemotherapy in early breast cancer patients. Results from GONO-MIG-1 Trial" Journal of National Cancer Institute  97 (23): 1724-1733, 2005

2004

• F. Roila and The Italian Group for Antiemetic Research (including C. Caroti) "Transferring scientific evidence to oncological practice: a trial of the impact of three different implementation strategies on prescription" Supportive Care Cancer 12 : 446-453, 2004
• Belvedere O, Puglisi F, Di Loreto C, Cataldi P, Guglielmi A, Aschele C, Sobrero A. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. Ann Oncol. 2004 Jan;15(1):55-8
• Serrano D, Perego E, Costa A, Decensi A. Progress in chemoprevention of breast cancer. Crit Rev Oncol Hematol. 2004 Feb;49(2):109-17
• Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res. 2004 Apr 1;10(7):2336-43
• Decensi A, Bonanni B, Baglietto L, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Robertson C, Marinucci I, Mariette F, Sandri MT, Daldoss C, Bianco V, Buttarelli M, Cazzaniga M, Franchi D, Cassano E, Omodei U.  A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res. 2004 Jul 1;10(13):4389-97
• Puntoni R, Ceppi M, Gennaro V, Ugolini D, Puntoni M, La Manna G, Casella C, Merlo DF. Occupational exposure to carbon black and risk of cancer. Cancer Causes Control. 2004 Jun;15(5):511-6
• Jodrell DI, Evans TR, Steward W, Cameron D, Prendiville J, Aschele C, Noberasco C, Lind M, Carmichael J, Dobbs N, Camboni G, Gatti B, De Braud F. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. Eur J Cancer. 2004 Aug;40(12):1872-7
• Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, Inglese ML, Volpe S, Ratto S, Dagna-Bricarelli F, Baldo C, Argusti A, Odetti P, Piccini A, Tabaton M. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology. 2004 Sep 14;63(5):828-31
• Aschele C, Debernardis D, Lonardi S, Bandelloni R, Casazza S, Monfardini S, Gallo L. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. J Clin Oncol. 2004 Sep 15;22(18):3758-65
• Johansson H, Baglietto L, Guerrieri-Gonzaga A, Bonanni B, Mariette F, Macis D, Serrano D, Sandri MT, Decensi A. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. Breast Cancer Res Treat. 2004 Nov;88(1):63-73
• Serrano D, Lazzeroni M, Decensi A. Chemoprevention of colorectal cancer: an update. Tech Coloproctol. 2004 Dec;8 Suppl 2:s248-52